EMEA and Gene Therapy Medicinal Products Development in the European Union
AUTOR(ES)
Papaluca Amati, Marisa
FONTE
Hindawi Publishing Corporation
RESUMO
The evaluation of quality, safety, and efficacy of medicinal products by the European Medicines Evaluation Agency (EMEA) via the centralized procedure is the only available regulatory procedure for obtaining marketing authorization for gene therapy (GT) medicinal products in the European Union. The responsibility for the authorization of clinical trials remains with the national competent authorities (NCA) acting in a harmonized framework from the scientific viewpoint. With the entry into force of a new directive on good clinical practice implementation in clinical trials as of 1 May 2004, procedural aspects will also be harmonized at EU level. Scientifically sound development of medicinal products is the key for the successful registration of dossiers and for contributing to the promotion and protection of public health. The objective of this paper is to introduce the EMEA regulatory processes and scientific activities relevant to GT medicinal products.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=179762Documentos Relacionados
- Proposals for model-based paediatric medicinal development within the current European Union regulatory framework
- Medicinal chemistry in the development of societies. Biodiversity and natural products
- Symbiont Succession during Embryonic Development of the European Medicinal Leech, Hirudo verbana▿
- The European Union's Superpower Revisited
- Regionalism and political pepresentation in comparativeperspective: the European Union and MERCOSUL